CAOT 31 Lecture Notes - Lecture 12: Pharmaceutical Industry, Drug Delivery, Risk Assessment
4 Oct 2020
School
Department
Course
Professor
Document Summary
> the manufacture of biomolecules, the use of biomolecules for the manufacture of other products, the application of biomolecules, the detection and measurement of biomolecules. > industrial sector : human and animal, agriculture, energy, environment, food. > very unique : diversity of customers and product bases. > products having very lengthy (10-15years), costly ((-800m and still increasing) and risky (for every drug brought to market there are 5,000 10,000 unsuccessfulcompounds screened) development cycles. New partnerships to help deliver novel solutions and prove value. Closer collaboration with providers, payers, regulators and patients. New growth opportunities with different business models. Ever increasing demand - with chronic disease burden increasing. Major reforms and new delivery models aiming to limit costs. Technology is a driving force for change. Flexible pricing with new pay for performance business models. Assess safety and biological activity in laboratory and animal studies. Confirm safety and efficacy in larger patient groups (1000-3000)
